<DOC>
	<DOCNO>NCT00702923</DOCNO>
	<brief_summary>The current protocol evaluate safety combine treatment bicalutamide ( Casodex ) CP-675,206 ( anti-CTLA-4 monoclonal antibody ) patient PSA-recurrent non-metastatic ( stage D0 ) prostate cancer . This dose escalation study safety primary endpoint . Secondary endpoint determine whether prostate associate immune response see , whether treatment associate increase PSA double time PSA recurrence one year , marker clinical activity . Cohorts six patient treat dose level . The investigator hypothesize short-term androgen deprivation therapy elicit prostate cancer-associated T-cell mediate tissue destruction augment monoclonal antibody block CTLA-4 , therapeutic benefit patient recurrent prostate cancer .</brief_summary>
	<brief_title>CP-675,206 Combination With Short Term Androgen Deprivation Patients With Stage D0 Prostate Cancer</brief_title>
	<detailed_description>This open label , single-center Phase I study . All subject receive bicalutamide 150mg orally day 1-28 . Subjects receive CP-675,206 IV one hour day 29 . Doses range 6 mg/kg 15 mg/kg . This cycle repeat month 3 . Once maximum tolerate dose determine , 6 additional subject enrol .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>At least 18 year age &amp; histologic diagnosis adenocarcinoma prostate Completed surgery radiation least 8 week prior entry removal visible disease Clinical Stage D0 prostate cancer rise PSA PSA &gt; 2ng/ml . ECOG performance &lt; 2 Normal hematologic , renal liver function Can evidence immunosuppression treat immunosuppressive therapy . No prior treatment LHRH agonist nonsteroidal antiandrogen casodex flutamide No evidence metastatic disease per bone scan CT scan abdomen pelvis No prior treatment antiCTLA 4 monoclonal antibody No history know autoimmune disorder HIV , hepatitis B hepatitis C No known brain metastases No history inflammatory bowel condition include diverticulitis , ulcerative colitis , etc .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Stage D0 Prostate Cancer</keyword>
	<keyword>Rising PSA</keyword>
	<keyword>Casodex</keyword>
	<keyword>Tremelimumab</keyword>
</DOC>